Cardiovascular Disease Risk in Adult Women with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

ABSTRACT

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a common autosomal recessive disorder characterized by impaired cortisol biosynthesis, with or without aldosterone deficiency, and androgen excess. Patients with the classic (severe) form also have epinephrine deficiency. Patients with CAH have an increased prevalence of risk factors for cardiovascular disease including obesity, hypertension, and insulin resistance. Androgen excess in women appears to be an additional risk factor for cardiovascular disease. Carotid intima-media thickness, a measure of subclinical atherosclerosis, also has been found to be increased in adults with CAH. The multiple hormonal imbalances present in the adult woman with CAH, in combination with chronic glucocorticoid therapy, contribute to cardiovascular disease risk. Further investigation of the predisposition to cardiovascular disease in women with CAH is warranted. Longitudinal studies are needed, and interventions targeting obesity, insulin resistance, hypertension, and hyperandrogenism may offer improved outcome.

KEYWORDS

Cardiovascular risk - congenital adrenal hyperplasia - metabolic syndrome - hyperandrogenism

REFERENCES

• 1 Merke D P, Bornstein S R. Congenital adrenal hyperplasia.  Lancet. 2005;  365 2125-2136
• 2 Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome.  Fertil Steril. 2006;  86(Suppl 1) S20-S21
• 3 Orio Jr F, Palomba S, Spinelli L et al.. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.  J Clin Endocrinol Metab. 2004;  89 3696-3701
• 4 National Institutes of Health .Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01–3670. Bethesda, MD; National Institutes of Health 2001
• 5 Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome.  J Endocrinol Invest. 2008;  31 400-405
• 6 Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome.  Pituitary. 2004;  7 253-256
• 7 Merke D P. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 2008;  93 653-660
• 8 Debono M, Ghobadi C, Rostami-Hodjegan A et al.. Modified-release hydrocortisone to provide circadian cortisol profiles.  J Clin Endocrinol Metab. 2009;  94 1548-1554
• 9 Chen M J, Yang W S, Yang J H, Chen C L, Ho H N, Yang Y S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.  Hypertension. 2007;  49 1442-1447
• 10 Mantzoros C S, Georgiadis E I, Young R et al.. Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women.  Am J Hypertens. 1995;  8 606-614
• 11 Wild R A, Applebaum-Bowden D, Demers L M et al.. Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen.  Clin Chem. 1990;  36 283-289
• 12 Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome.  Semin Reprod Med. 2008;  26 39-44
• 13 Huppert J, Chiodi M, Hillard P J. Clinical and metabolic findings in adolescent females with hyperandrogenism.  J Pediatr Adolesc Gynecol. 2004;  17 103-108
• 14 Golden S H, Ding J, Szklo M, Schmidt M I, Duncan B B, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study.  Am J Epidemiol. 2004;  160 540-548
• 15 Moghetti P, Tosi F, Castello R et al.. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.  J Clin Endocrinol Metab. 1996;  81 952-960
• 16 Nestler J E. Metformin for the treatment of the polycystic ovary syndrome.  N Engl J Med. 2008;  358 47-54
• 17 Charmandari E, Weise M, Bornstein S R et al.. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.  J Clin Endocrinol Metab. 2002;  87 2114-2120
• 18 Sartorato P, Zulian E, Benedini S et al.. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 2007;  92 1015-1018
• 19 Falhammar H, Filipsson H, Holmdahl G et al.. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 2007;  92 110-116
• 20 Speiser P W, Serrat J, New M I, Gertner J M. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 1992;  75 1421-1424
• 21 Saygili F, Oge A, Yilmaz C. Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between serum leptin levels and chronic hyperinsulinemia.  Horm Res. 2005;  63 270-274
• 22 Bachelot A, Plu-Bureau G, Thibaud E et al.. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Horm Res. 2007;  67 268-276
• 23 Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism.  Diabetologia. 2000;  43 533-549
• 24 Riepe F G, Krone N, Krüger S N et al.. Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Exp Clin Endocrinol Diabetes. 2006;  114 105-110
• 25 Weise M, Mehlinger S L, Drinkard B et al.. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise.  J Clin Endocrinol Metab. 2004;  89 591-597
• 26 Niswender K D, Magnuson M A. Obesity and the beta cell: lessons from leptin.  J Clin Invest. 2007;  117 2753-2756
• 27 Martikainen H, Salmela P, Nuojua-Huttunen S et al.. Adrenal steroidogenesis is related to insulin in hyperandrogenic women.  Fertil Steril. 1996;  66 564-570
• 28 New M I. Polycystic ovarian disease and congenital and late-onset adrenal hyperplasia.  Endocrinol Metab Clin North Am. 1988;  17 637-648
• 29 Hague W M, Adams J, Rodda C et al.. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives.  Clin Endocrinol (Oxf). 1990;  33 501-510
• 30 Ogden C L, Flegal K M, Carroll M D, Johnson C L. Prevalence and trends in overweight among US children and adolescents, 1999-2000.  JAMA. 2002;  288 1728-1732
• 31 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999-2000.  JAMA. 2002;  288 1723-1727
• 32 Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
• 33 National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report.  Obes Res. 1998;  6(Suppl 2) 51S-209S
• 34 Burke V, Beilin L J, Simmer K et al.. Predictors of body mass index and associations with cardiovascular risk factors in Australian children: a prospective cohort study.  Int J Obes (Lond). 2005;  29 15-23
• 35 Weiss R, Dufour S, Taksali S E et al.. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning.  Lancet. 2003;  362 951-957
• 36 Wajchenberg B L, Giannella-Neto D, da Silva M E, Santos R F. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome.  Horm Metab Res. 2002;  34 616-621
• 37 Stikkelbroeck N M, Oyen W J, van der Wilt G J, Hermus A R, Otten B J. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 2003;  88 1036-1042
• 38 Christiansen P, Mølgaard C, Müller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Horm Res. 2004;  61 133-136
• 39 Hagenfeldt K, Martin Ritzén E, Ringertz H, Helleday J, Carlström K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy.  Eur J Endocrinol. 2000;  143 667-671
• 40 Cornean R E, Hindmarsh P C, Brook C G. Obesity in 21-hydroxylase deficient patients.  Arch Dis Child. 1998;  78 261-263
• 41 Völkl T M, Simm D, Beier C, Dörr H G. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Pediatrics. 2006;  117 e98-e105
• 42 Isguven P, Arslanoglu I, Mesutoglu N, Yildiz M, Erguven M. Bioelectrical impedance analysis of body fatness in childhood congenital adrenal hyperplasia and its metabolic correlates.  Eur J Pediatr. 2008;  167 1263-1268
• 43 Pasquali R, Vicennati V, Gambineri A, Pagotto U. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity.  Int J Obes (Lond). 2008;  32 1764-1779
• 44 Roche E F, Charmandari E, Dattani M T, Hindmarsh P C. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.  Clin Endocrinol (Oxf). 2003;  58 589-596
• 45 Völkl T M, Simm D, Dötsch J, Rascher W, Dörr H G. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 2006;  91 4888-4895
• 46 Nebesio T D, Eugster E A. Observation of hypertension in children with 21-hydroxylase deficiency: a preliminary report.  Endocrine. 2006;  30 279-282
• 47 Botero D, Arango A, Danon M, Lifshitz F. Lipid profile in congenital adrenal hyperplasia.  Metabolism. 2000;  49 790-793
• 48 Bloomgarden Z T. Inflammation and insulin resistance.  Diabetes Care. 2003;  26 1922-1926
• 49 Hajer G R, van Haeften T W, Visseren F L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.  Eur Heart J. 2008;  29 2959-2971
• 50 Witchel S F, DeFranco D B. Mechanisms of disease: regulation of glucocorticoid and receptor levels—impact on the metabolic syndrome.  Nat Clin Pract Endocrinol Metab. 2006;  2 621-631